An Expanded Access Program (EAP) allows physicians and patients access to much needed medicines when there are no other viable options left. These may be investigational therapies as well as drugs not available in the patient’s country and the ultimate intention is to treat unmet clinical need.
An EAP can also be known as a Managed Access Program (MAP), Early Access Program, Compassionate Use Program, Named Patient Program (NPP). Essentially, they all describe the provision of an unlicensed medication from another country to patients that have no local alternative.
EAPs fall broadly into two main groups:
Pre-Approval EAPs provide medicines:
Post-Approval EAPs provide medicines that:
For more information contact:
+1 919 694 5088
+44 208 004 8186